Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

E. Dadachova, B. Bouzahzah, L. S. Zuckier, R. G. Pestell

Research output: Contribution to journalArticle

74 Scopus citations


The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal 188Re in the form of 188Re-perrhenate was therefore compared with 131I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, 188Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that 188Re-perrhenate is able to deliver a dose 4.5 times higher than 131I suggesting it may provide enhanced therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalNuclear Medicine and Biology
Issue number1
StatePublished - Feb 2 2002



  • Iodide symporter (NIS)
  • Iodine
  • Mammary tumor
  • Radiation dose
  • Rhenium
  • Sodium
  • Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this